Bollard Group’s CONMED CNMD Stock Holding History

Bollard Group’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,408	Closed	-$209K	–	312
2022 Q1	$209K	Hold	1,408	–	–	0.01%	233
2021 Q4	$200K	Hold	1,408	–	–	0.01%	234
2021 Q3	$184K	Hold	1,408	–	–	0.01%	237
2021 Q2	$194K	Hold	1,408	–	–	0.01%	226
2021 Q1	$184K	Hold	1,408	–	–	0.01%	224
2020 Q4	$158K	Hold	1,408	–	–	0.01%	226
2020 Q3	$111K	Hold	1,408	–	–	﹤0.01%	236
2020 Q2	$101K	Buy	+1,408	New	+$98K	﹤0.01%	247

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bollard Group's CNMD Position: Q2 2022 in Review

Bollard Group sold out of CONMED (CNMD) in Q2 2022, closing a stake of 1,408 shares — an estimated $209K sold.

Bollard Group first reported a position in CNMD in Q2 2020 and held it in 8 quarters. The position peaked at $209K in Q1 2022. 280 funds tracked by Wall St. Rank hold CNMD as of Q2 2022.

Bollard Group reported no remaining CONMED position as of Q2 2022 after selling out during the quarter.
Bollard Group sold 1,408 CONMED shares in Q2 2022, an estimated $209K.
Bollard Group first reported a position in CONMED in Q2 2020 and held it in 8 quarters.
Bollard Group's CONMED position peaked at $209K in Q1 2022.
280 funds tracked by Wall St. Rank held CONMED as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.